|
1
|
Jemal A, Siegel R, Xu J and Ward E: Cancer
statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wang BH, Cao WM, Yu J and Wang XL:
Gemcitabine-based concurrent chemoradiotherapy versus chemotherapy
alone in patients with locally advanced pancreatic cancer. Asian
Pac J Cancer Prev. 13:2129–2132. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Matthaios D, Zarogoulidis P, Balgouranidou
I, Chatzaki E and Kakolyris S: Molecular pathogenesis of pancreatic
cancer and clinical perspectives. Oncology. 81:259–272. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sehara Y, Sawicka K, Hwang JY,
Latuszek-Barrantes A, Etgen AM and Zukin RS: Survivin is a
transcriptional target of STAT3 critical to estradiol
neuroprotection in global ischemia. J Neurosci. 33:12364–12374.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yu H and Jove R: The STATs of cancer-new
molecular targets come of age. Nat Rev Cancer. 4:97–105. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Takezawa K, Okamoto I, Nishio K, Jänne PA
and Nakagawa K: Role of ERK-BIM and STAT3-survivin signaling
pathways in ALK inhibitor-induced apoptosis in EML4-ALK-positive
lung cancer. Clin Cancer Res. 17:2140–2148. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lesina M, Kurkowski MU, Ludes K, Rose-John
S, Treiber M, Klöppel G, Yoshimura A, Reindl W, Sipos B, Akira S,
et al: Stat3/Socs3 activation by IL-6 transsignaling promotes
progression of pancreatic intraepithelial neoplasia and development
of pancreatic cancer. Cancer Cell. 19:456–469. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Nagaraj NS, Washington MK and Merchant NB:
Combined blockade of Src kinase and epidermal growth factor
receptor with gemcitabine overcomes STAT3-mediated resistance of
inhibition of pancreatic tumor growth. Clin Cancer Res. 17:483–493.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Li HD, Huang C, Huang KJ, Wu WD, Jiang T,
Cao J, Feng ZZ and Qiu ZJ: STAT3 knockdown reduces pancreatic
cancer cell invasiveness and matrix metalloproteinase-7 expression
in nude mice. PLoS One. 6:e259412011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Huang S and Sinicrope FA: Sorafenib
inhibits STAT3 activation to enhance TRAIL-mediated apoptosis in
human pancreatic cancer cells. Mol Cancer Ther. 9:742–750. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Park IJ, Kim MJ, Park OJ, Choe W, Kang I,
Kim SS and Ha J: Cryptotanshinone induces ER stress-mediated
apoptosis in HepG2 and MCF7 cells. Apoptosis. 17:248–257. 2012.
View Article : Google Scholar
|
|
12
|
Ge Y, Cheng R, Zhou Y, Shen J, Peng L, Xu
X, Dai Q, Liu P, Wang H, Ma X, et al: Cryptotanshinone induces cell
cycle arrest and apoptosis of multidrug resistant human chronic
myeloid leukemia cells by inhibiting the activity of eukaryotic
initiation factor 4E. Mol Cell Biochem. 368:17–25. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chen W, Luo Y, Liu L, Zhou H, Xu B, Han X,
Shen T, Liu Z, Lu Y and Huang S: Cryptotanshinone inhibits cancer
cell proliferation by suppressing Mammalian target of
rapamycin-mediated cyclin D1 expression and Rb phosphorylation.
Cancer Prev Res (Phila). 3:1015–1025. 2010. View Article : Google Scholar
|
|
14
|
Shin DS, Kim HN, Shin KD, Yoon YJ, Kim SJ,
Han DC and Kwon BM: Cryptotanshinone inhibits constitutive signal
transducer and activator of transcription 3 function through
blocking the dimerization in DU145 prostate cancer cells. Cancer
Res. 69:193–202. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lu L, Li C, Li D, Wang Y, Zhou C, Shao W,
Peng J, You Y, Zhang X and Shen X: Cryptotanshinone inhibits human
glioma cell proliferation by suppressing STAT3 signaling. Mol Cell
Biochem. 381:273–282. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ge Y, Yang B, Xu X, Dai Q, Chen Z and
Cheng R: Cryptotanshinone acts synergistically with imatinib to
induce apoptosis of human chronic myeloid leukemia cells. Leuk
Lymphoma. 56:730–738. 2015. View Article : Google Scholar
|
|
17
|
Papanikolaou V, Iliopoulos D, Dimou I,
Dubos S, Kappas C, Kitsiou-Tzeli S and Tsezou A: Survivin
regulation by HER2 through NF-κB and c-myc in irradiated breast
cancer cells. J Cell Mol Med. 15:1542–1550. 2011. View Article : Google Scholar
|
|
18
|
Sun M, Liu C, Nadiminty N, Lou W, Zhu Y,
Yang J, Evans CP, Zhou Q and Gao AC: Inhibition of Stat3 activation
by sanguinarine suppresses prostate cancer cell growth and
invasion. Prostate. 72:82–89. 2012. View Article : Google Scholar
|
|
19
|
Cao H, LE D and Yang LX: Current status in
chemotherapy for advanced pancreatic adenocarcinoma. Anticancer
Res. 33:1785–1791. 2013.PubMed/NCBI
|
|
20
|
Schüler S, Diersch S, Hamacher R, Schmid
RM, Saur D and Schneider G: SKP2 confers resistance of pancreatic
cancer cells towards TRAIL-induced apoptosis. Int J Oncol.
38:219–225. 2011.
|
|
21
|
Pandurangan AK and Esa NM: Signal
transducer and activator of transcription 3-a promising target in
colitis-associated cancer. Asian Pac J Cancer Prev. 15:551–560.
2014. View Article : Google Scholar
|
|
22
|
Don MJ, Liao JF, Lin LY and Chiou WF:
Cryptotanshinone inhibits chemotactic migration in macrophages
through negative regulation of the PI3K signaling pathway. Br J
Pharmacol. 151:638–646. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ge YQ, Xu XF, Yang B, Chen Z and Cheng RB:
Saponins from Rubus parvifolius L. induce apoptosis in human
chronic myeloid leukemia cells through AMPK activation and STAT3
inhibition. Asian Pac J Cancer Prev. 15:5455–5461. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhang J, Wang P, Ouyang H, Yin J, Liu A,
Ma C and Liu L: Targeting cancer-related inflammation: Chinese
herbal medicine inhibits epithelial -to- mesenchymal transition in
pancreatic cancer. PLoS One. 8:e703342013. View Article : Google Scholar
|
|
25
|
Chen L, Wang HJ, Xie W, Yao Y, Zhang YS
and Wang H: Cryptotanshinone inhibits lung tumorigenesis and
induces apoptosis in cancer cells in vitro and in vivo. Mol Med
Rep. 9:2447–2452. 2014.PubMed/NCBI
|
|
26
|
Von Hoff DD, Ervin T, Arena FP, Chiorean
EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, et
al: Increased survival in pancreatic cancer with nab-paclitaxel
plus gemcitabine. N Engl J Med. 369:1691–1703. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wang ZH, Chen H, Guo HC, Tong HF, Liu JX,
Wei WT, Tan W, Ni ZL, Liu HB and Lin SZ: Enhanced antitumor
efficacy by the combination of emodin and gemcitabine against human
pancreatic cancer cells via downregulation of the expression of
XIAP in vitro and in vivo. Int J Oncol. 39:1123–1131.
2011.PubMed/NCBI
|
|
28
|
Liu A, Chen H, Tong H, Ye S, Qiu M, Wang
Z, Tan W, Liu J and Lin S: Emodin potentiates the antitumor effects
of gemcitabine in pancreatic cancer cells via inhibition of nuclear
factor-κB. Mol Med Rep. 4:221–227. 2011.PubMed/NCBI
|
